Trastuzumab cardiotoxicity: Biological hypotheses and clinical open issues

Emilio Bria, Federica Cuppone, Michele Milella, Sunil Verma, Paolo Carlini, Cecilia Nisticò, Vanja Vaccaro, Antonio Rossi, Giuseppe Tonini, Francesco Cognetti, Edmondo Terzoli

Research output: Contribution to journalArticle

Abstract

Background: Trastuzumab has significantly improved the prognosis of breast cancer patients overexpressing the human epidermal growth factor receptor 2 (HER2). This result has been achieved in all disease settings, by increasing overall survival in early stage and advanced disease and by increasing pathological complete responses in neoadjuvant disease. Objective: Although the greatest impact of this monoclonal antibody has been seen in the adjuvant setting, by increasing disease-free survival and overall survival rates an increased rate of both symptomatic and nonsymptomatic cardiac toxicity has also been observed. Methods: In the following review, the different mechanisms of trastuzumab cardiac toxicity are described and, in addition, the clinical data coming from both trials and meta-analyses is discussed. Results: While there is strong evidence for the incidence of trastuzumab-related cardiac toxicity, there is still little known on the exact pathogenesis of this toxicity. Interestingly, both experimental and clinical data suggest that trastuzumab may sensitize cardiomyocytes to injuries and stress from administration of anthracyclines. This has led to a proposed novel mechanism of cardiotoxicity that appears to be quite different from the anthracycline-associated cardiotoxicity. Trastuzumab does not seem to cause any overt ultrastructural abnormality; it does, however, lead to myocardial dysfunction. Conclusion: Most of the proposed hypotheses seems to be related to the activity of trastuzumab in interfering with the ERBB-2 receptor. Indeed, data from clinical trials in the adjuvant setting report increased cardiac toxicity in those patients who previously received anthracyclines.

Original languageEnglish
Pages (from-to)1963-1971
Number of pages9
JournalExpert Opinion on Biological Therapy
Volume8
Issue number12
DOIs
Publication statusPublished - Dec 2008

Fingerprint

Toxicity
Anthracyclines
Cardiac Myocytes
Disease-Free Survival
Meta-Analysis
Trastuzumab
Cardiotoxicity
Survival Rate
Monoclonal Antibodies
Clinical Trials
Breast Neoplasms
Survival
Incidence
Wounds and Injuries

Keywords

  • Cardiotoxicity
  • Review
  • Trastuzumab

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Trastuzumab cardiotoxicity : Biological hypotheses and clinical open issues. / Bria, Emilio; Cuppone, Federica; Milella, Michele; Verma, Sunil; Carlini, Paolo; Nisticò, Cecilia; Vaccaro, Vanja; Rossi, Antonio; Tonini, Giuseppe; Cognetti, Francesco; Terzoli, Edmondo.

In: Expert Opinion on Biological Therapy, Vol. 8, No. 12, 12.2008, p. 1963-1971.

Research output: Contribution to journalArticle

Bria, E, Cuppone, F, Milella, M, Verma, S, Carlini, P, Nisticò, C, Vaccaro, V, Rossi, A, Tonini, G, Cognetti, F & Terzoli, E 2008, 'Trastuzumab cardiotoxicity: Biological hypotheses and clinical open issues', Expert Opinion on Biological Therapy, vol. 8, no. 12, pp. 1963-1971. https://doi.org/10.1517/14728220802517935
Bria, Emilio ; Cuppone, Federica ; Milella, Michele ; Verma, Sunil ; Carlini, Paolo ; Nisticò, Cecilia ; Vaccaro, Vanja ; Rossi, Antonio ; Tonini, Giuseppe ; Cognetti, Francesco ; Terzoli, Edmondo. / Trastuzumab cardiotoxicity : Biological hypotheses and clinical open issues. In: Expert Opinion on Biological Therapy. 2008 ; Vol. 8, No. 12. pp. 1963-1971.
@article{f020e4e8d06845f4a29ef77ffb7b52c3,
title = "Trastuzumab cardiotoxicity: Biological hypotheses and clinical open issues",
abstract = "Background: Trastuzumab has significantly improved the prognosis of breast cancer patients overexpressing the human epidermal growth factor receptor 2 (HER2). This result has been achieved in all disease settings, by increasing overall survival in early stage and advanced disease and by increasing pathological complete responses in neoadjuvant disease. Objective: Although the greatest impact of this monoclonal antibody has been seen in the adjuvant setting, by increasing disease-free survival and overall survival rates an increased rate of both symptomatic and nonsymptomatic cardiac toxicity has also been observed. Methods: In the following review, the different mechanisms of trastuzumab cardiac toxicity are described and, in addition, the clinical data coming from both trials and meta-analyses is discussed. Results: While there is strong evidence for the incidence of trastuzumab-related cardiac toxicity, there is still little known on the exact pathogenesis of this toxicity. Interestingly, both experimental and clinical data suggest that trastuzumab may sensitize cardiomyocytes to injuries and stress from administration of anthracyclines. This has led to a proposed novel mechanism of cardiotoxicity that appears to be quite different from the anthracycline-associated cardiotoxicity. Trastuzumab does not seem to cause any overt ultrastructural abnormality; it does, however, lead to myocardial dysfunction. Conclusion: Most of the proposed hypotheses seems to be related to the activity of trastuzumab in interfering with the ERBB-2 receptor. Indeed, data from clinical trials in the adjuvant setting report increased cardiac toxicity in those patients who previously received anthracyclines.",
keywords = "Cardiotoxicity, Review, Trastuzumab",
author = "Emilio Bria and Federica Cuppone and Michele Milella and Sunil Verma and Paolo Carlini and Cecilia Nistic{\`o} and Vanja Vaccaro and Antonio Rossi and Giuseppe Tonini and Francesco Cognetti and Edmondo Terzoli",
year = "2008",
month = "12",
doi = "10.1517/14728220802517935",
language = "English",
volume = "8",
pages = "1963--1971",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "12",

}

TY - JOUR

T1 - Trastuzumab cardiotoxicity

T2 - Biological hypotheses and clinical open issues

AU - Bria, Emilio

AU - Cuppone, Federica

AU - Milella, Michele

AU - Verma, Sunil

AU - Carlini, Paolo

AU - Nisticò, Cecilia

AU - Vaccaro, Vanja

AU - Rossi, Antonio

AU - Tonini, Giuseppe

AU - Cognetti, Francesco

AU - Terzoli, Edmondo

PY - 2008/12

Y1 - 2008/12

N2 - Background: Trastuzumab has significantly improved the prognosis of breast cancer patients overexpressing the human epidermal growth factor receptor 2 (HER2). This result has been achieved in all disease settings, by increasing overall survival in early stage and advanced disease and by increasing pathological complete responses in neoadjuvant disease. Objective: Although the greatest impact of this monoclonal antibody has been seen in the adjuvant setting, by increasing disease-free survival and overall survival rates an increased rate of both symptomatic and nonsymptomatic cardiac toxicity has also been observed. Methods: In the following review, the different mechanisms of trastuzumab cardiac toxicity are described and, in addition, the clinical data coming from both trials and meta-analyses is discussed. Results: While there is strong evidence for the incidence of trastuzumab-related cardiac toxicity, there is still little known on the exact pathogenesis of this toxicity. Interestingly, both experimental and clinical data suggest that trastuzumab may sensitize cardiomyocytes to injuries and stress from administration of anthracyclines. This has led to a proposed novel mechanism of cardiotoxicity that appears to be quite different from the anthracycline-associated cardiotoxicity. Trastuzumab does not seem to cause any overt ultrastructural abnormality; it does, however, lead to myocardial dysfunction. Conclusion: Most of the proposed hypotheses seems to be related to the activity of trastuzumab in interfering with the ERBB-2 receptor. Indeed, data from clinical trials in the adjuvant setting report increased cardiac toxicity in those patients who previously received anthracyclines.

AB - Background: Trastuzumab has significantly improved the prognosis of breast cancer patients overexpressing the human epidermal growth factor receptor 2 (HER2). This result has been achieved in all disease settings, by increasing overall survival in early stage and advanced disease and by increasing pathological complete responses in neoadjuvant disease. Objective: Although the greatest impact of this monoclonal antibody has been seen in the adjuvant setting, by increasing disease-free survival and overall survival rates an increased rate of both symptomatic and nonsymptomatic cardiac toxicity has also been observed. Methods: In the following review, the different mechanisms of trastuzumab cardiac toxicity are described and, in addition, the clinical data coming from both trials and meta-analyses is discussed. Results: While there is strong evidence for the incidence of trastuzumab-related cardiac toxicity, there is still little known on the exact pathogenesis of this toxicity. Interestingly, both experimental and clinical data suggest that trastuzumab may sensitize cardiomyocytes to injuries and stress from administration of anthracyclines. This has led to a proposed novel mechanism of cardiotoxicity that appears to be quite different from the anthracycline-associated cardiotoxicity. Trastuzumab does not seem to cause any overt ultrastructural abnormality; it does, however, lead to myocardial dysfunction. Conclusion: Most of the proposed hypotheses seems to be related to the activity of trastuzumab in interfering with the ERBB-2 receptor. Indeed, data from clinical trials in the adjuvant setting report increased cardiac toxicity in those patients who previously received anthracyclines.

KW - Cardiotoxicity

KW - Review

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=57649177401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57649177401&partnerID=8YFLogxK

U2 - 10.1517/14728220802517935

DO - 10.1517/14728220802517935

M3 - Article

C2 - 18990083

AN - SCOPUS:57649177401

VL - 8

SP - 1963

EP - 1971

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 12

ER -